CanSino Biologics (SHSE:688185) Net Issuance of Debt : ¥217.7 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. CanSino Biologics's net issuance of debt for the three months ended in Mar. 2024 was ¥166.1 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was ¥217.7 Mil.

CanSino Biologics Net Issuance of Debt Historical Data

The historical data trend for CanSino Biologics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Net Issuance of Debt Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

-20.00

990.13

1,268.65

69.28

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Debt	Get a 7-Day Free Trial													17.62	-209.94	103.58	158.02	166.07

CanSino Biologics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥217.7 Mil.

CanSino Biologics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (SHSE:688185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Net Issuance of Debt

Traded in Other Exchanges

CASBF:USA 06185:Hong Kong CJH:Germany

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (SHSE:688185) Headlines

No Headlines